What is Sift Bio?
Sift Bio operates at the intersection of artificial intelligence and precision medicine, specializing in the development of immunotherapy boosters designed to augment the efficacy of existing cancer treatments. The company utilizes a sophisticated technological stack that combines high-throughput cellular screening with advanced machine learning algorithms to identify and optimize therapeutic candidates. By focusing on the enhancement of immune cell performance, Sift Bio addresses one of the most significant challenges in modern oncology: the resistance of tumor microenvironments to conventional therapeutic interventions. This strategic focus positions the company as a high-value player in the biopharmaceutical ecosystem, particularly as the industry shifts toward personalized, patient-centric care models that prioritize improved clinical outcomes.
How much funding has Sift Bio raised?
Sift Bio has raised a total of $3.7M across 1 funding round:
Angel/Pre-Seed
$3.7M
Angel/Pre-Seed (2026): $3.7M with participation from Lifespan Vision Ventures, Freeflow Ventures, and Eisai Innovation, Inc.
Key Investors in Sift Bio
Lifespan Vision Ventures
A venture firm focused on diagnostics and therapeutics aimed at longevity and aging reversal, supporting technologies that extend the human health span.
Freeflow Ventures
An early-stage firm originating from the Caltech ecosystem, specializing in deep tech solutions that leverage AI and machine learning to address human health challenges.
Eisai Innovation, Inc.
The corporate venture arm of a leading global pharmaceutical company, dedicated to investing in innovative solutions for oncology and neurology with high unmet medical needs.
What's next for Sift Bio?
With the recent influx of capital, Sift Bio is expected to scale its laboratory operations and expand its computational infrastructure to support a broader range of therapeutic targets. The company's roadmap likely includes the advancement of lead candidates into preclinical trials, where the focus will be on demonstrating the scalability and safety of their immunotherapy boosters. Furthermore, the strategic backing from specialized life sciences investors suggests a potential for future collaborative partnerships with global pharmaceutical entities. As Sift Bio continues to refine its AI-driven discovery engine, the firm is poised to play a transformative role in the next generation of cancer care, potentially shortening the development cycle for life-saving treatments and establishing a sustainable competitive moat in the crowded immunotherapy market.
See full Sift Bio company page
